These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37256275)

  • 61. Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.
    Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Shayesteh Alam M; Papp KA; Desjardins O; Jean C
    J Cutan Med Surg; 2022; 26(4):361-370. PubMed ID: 35322692
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Arguments for a national questionnaire-based screening for hidradenitis suppurativa in Denmark.
    Theut Riis P; Lindsø Andersen P; Jemec GB
    Acta Dermatovenerol Alp Pannonica Adriat; 2018 Sep; 27(3):115-120. PubMed ID: 30244260
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Factors Affecting Treatment Selection Among Patients With Hidradenitis Suppurativa.
    Salame N; Sow YN; Siira MR; Garg A; Chen SC; Patzer RE; Kavalieratos D; Orenstein LAV
    JAMA Dermatol; 2024 Feb; 160(2):179-186. PubMed ID: 38198173
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.
    Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
    J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials.
    Lu JW; Huang YW; Chen TL
    Medicine (Baltimore); 2021 Jun; 100(22):e26190. PubMed ID: 34087885
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical Characteristics of Hidradenitis Suppurativa Patients from a Reference Centre in Kaunas, Lithuania.
    Kucinskiene V; Jariene V; Valiukeviciene S
    Dermatology; 2020; 236(1):66-70. PubMed ID: 31940646
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
    Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The management of pediatric hidradenitis suppurativa differs between dermatologic and non-dermatologic providers: A retrospective review.
    Atherton KM; Shope CN; Andrews LA; Robinson-Pirotte IS; Wine Lee L; Cotton CH
    Pediatr Dermatol; 2024; 41(1):28-33. PubMed ID: 38018236
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern.
    Pinter A; Sarlak M; Zeiner KN; Malisiewicz B; Kaufmann R; Romanelli M; Koenig A; Chiricozzi A
    Dermatology; 2021; 237(5):759-768. PubMed ID: 33326954
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hidradenitis Suppurativa and the Association With Hematological Malignancies.
    Sotoodian B; Abbas M; Brassard A
    J Cutan Med Surg; 2017; 21(2):158-161. PubMed ID: 27573126
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab.
    Caposiena Caro RD; Chiricozzi A; Sechi A; Molinelli E; Venturini M; Candi E; DE Simone C; Peris K; Patrizi A; Offidani A; Calzavara-Pinton P; Bianchi L
    Ital J Dermatol Venerol; 2022 Apr; 157(2):137-141. PubMed ID: 33982548
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience.
    Melgosa Ramos FJ; García Ruiz R; Mateu Puchades A; Alfageme Roldán F
    Dermatol Ther; 2022 Jul; 35(7):e15558. PubMed ID: 35510581
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation.
    Kozera EK; Porter M; Paek SY; Mintoff D; McMeniman E; Oon HH; Chandran NS; Glasenhardt K; Ring HC; Frew JW
    Dermatology; 2024; 240(3):494-506. PubMed ID: 37963431
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan.
    Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
    J Dermatol; 2023 Aug; 50(8):1034-1044. PubMed ID: 37264993
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
    Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P
    Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice.
    Montero-Vilchez T; Salvador-Rodriguez L; Sanchez-Diaz M; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A
    Dermatol Ther; 2020 Nov; 33(6):e14254. PubMed ID: 32860480
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
    Bechara FG; Podda M; Prens EP; Horváth B; Giamarellos-Bourboulis EJ; Alavi A; Szepietowski JC; Kirby J; Geng Z; Jean C; Jemec GBE; Zouboulis CC
    JAMA Surg; 2021 Nov; 156(11):1001-1009. PubMed ID: 34406349
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hidradenitis suppurativa managed with adalimumab.
    Yamauchi PS; Mau N
    J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.